Research Papers:

MicroRNA-26b attenuates monocrotaline-induced pulmonary vascular remodeling via targeting connective tissue growth factor (CTGF) and cyclin D1 (CCND1)

Ran Wang _, Xing Ding, Sijing Zhou, Min Li, Li Sun, Xuan Xu and Guanghe Fei

PDF  |  HTML  |  Supplementary Files  |  How to cite

Oncotarget. 2016; 7:72746-72757. https://doi.org/10.18632/oncotarget.10125

Metrics: PDF 1658 views  |   HTML 2087 views  |   ?  


Ran Wang1,*, Xing Ding1,*, Sijing Zhou2, Min Li3, Li Sun1, Xuan Xu4, Guanghe Fei1

1Department of Respiratory Medicine, The First Affiliated Hospital of Anhui Medical University, Hefei 230022, China

2Department of Occupational Diseases, Hefei Third Clinical College, Anhui Medical University, Hefei 230001, China

3Department of Oncology, The First Affiliated Hospital of Anhui Medical University, Hefei 230022, China

4Division of Pulmonary/Critical Care Medicine, Cedars Sinai Medical Center, Los Angeles, CA 90048, USA

*These authors have contributed equally to this work

Correspondence to:

Guanghe Fei, email: [email protected]

Keywords: miR-26b, CTGF, cyclin D1, monocrotaline, pulmonary hypertension

Received: December 05, 2015    Accepted: May 17, 2016    Published: June 17, 2016


MicroRNAs are involved in the control of cell growth, and deregulated pulmonary artery smooth muscle cell proliferation plays an essential role in the development of pulmonary hypertension. The objective of this study was to identify differentially expressed microRNA(s) and explore its therapeutic role in treatment of the disease. MicroRNA expression profile analysis showed microRNA-26b was differentially expressed in pulmonary artery smooth muscle cells harvested from monocrotaline-treated rats, and we validated microRNA-26b targets, in vitro and in vivo, CTGF and CCND1, both of which have been shown, in our previous work, to be involved in the pathogenesis of pulmonary hypertension. In vivo experiments demonstrated monocrotaline-induced pulmonary artery remodeling could be almost completely abolished by administration of microRNA-26b, while CTGF or CCND1 shRNA significantly, but only partially, attenuated the remodeling by silencing the designed target. Additionally, exogenous expression of the microRNA-26b substantially downregulated CTGF and CCND1 in human pulmonary artery smooth muscle cells. MicroRNA-26b might be a potent therapeutic tool to treat pulmonary hypertension.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 10125